Flag of the European Union EU Clinical Trials Register Help

Clinical trials for roche OR chugai OR genentech

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,190 result(s) found for: roche OR chugai OR genentech. Displaying page 147 of 160.
    «« First « Previous 143  144  145  146  147  148  149  150  151  Next» Last»»
    EudraCT Number: 2009-016197-33 Sponsor Protocol Number: 3.1 Start Date*: 2010-02-25
    Sponsor Name:Celltrion, Inc.
    Full Title: A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Me...
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-004281-71 Sponsor Protocol Number: 20070509 Start Date*: 2009-02-10
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously ...
    Medical condition: Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006188-22 Sponsor Protocol Number: GIMEMA-DSIL APL0406 Start Date*: 2007-07-10
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: A randomised phase III study to compare arsenic trioxide (ATO) combined to ATRA versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for newly diagnosed, non high-risk acute pro...
    Medical condition: Non high-risk acute promyelocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001019 Acute promyelocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003632-20 Sponsor Protocol Number: GS-US-320-4018 Start Date*: 2017-05-11
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with...
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003050-32 Sponsor Protocol Number: 205646 Start Date*: 2018-01-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo- Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subject...
    Medical condition: Systemic Lupus Erythematosus (SLE) or Lupus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002962-10 Sponsor Protocol Number: MO40599/GLA2017-R2 Start Date*: 2021-05-03
    Sponsor Name:GWT-TUD GmbH
    Full Title: An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and eto...
    Medical condition: primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10003901 B-cell lymphoma NOS LLT
    21.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    21.1 100000004864 10023769 Large cell immunoblastic lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002715-21 Sponsor Protocol Number: AIO-KRK-0220 Start Date*: 2021-10-22
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMR-deficient stage II high risk or stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy– a Phase II study (ANT...
    Medical condition: Patients with MSI-high or MMR-deficient stage III colorectal cancer who are ineligible for or who refuse oxaliplatin-based chemotherapy after R0 tumor resection (main study) or planned resection (s...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009955 Colon cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009966 Colon carcinoma stage III LLT
    22.0 10010331 - Congenital, familial and genetic disorders 10078672 DNA mismatch repair protein gene mutation PT
    21.0 10010331 - Congenital, familial and genetic disorders 10080676 Microsatellite instability LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001167 Adenocarcinoma of colon PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001171 Adenocarcinoma of colon stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010034 Colorectal cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007446 Carcinoma of rectum LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007450 Carcinoma of rectum stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007468 Carcinoma rectum stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014463-39 Sponsor Protocol Number: 1.1 Start Date*: 2009-12-01
    Sponsor Name:Celltrion, Inc.
    Full Title: A Double-blind Randomised, Parallel Phase I/IIb Study to Evaluate Initial Safety and Efficacy, Comparative Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) BG (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-002141-42 Sponsor Protocol Number: NL73593 Start Date*: 2020-07-03
    Sponsor Name:Catharina Hospital
    Full Title: Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for loc...
    Medical condition: Locally recurrent rectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) PT (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002014-16 Sponsor Protocol Number: VIR-MHB1-V200 Start Date*: 2023-05-17
    Sponsor Name:Vir Biotechnology, Inc.
    Full Title: A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)
    Medical condition: Chronic Hepatitis B Virus (HBV) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BG (Prematurely Ended) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000540-60 Sponsor Protocol Number: SGNTUC-017 Start Date*: 2020-08-10
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
    Medical condition: HER2+ Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002186-36 Sponsor Protocol Number: DSC-BROMS-1 Start Date*: 2021-05-26
    Sponsor Name:Uppsala University Hospital
    Full Title: A multicenter, open-label, randomized, phase I/II clinical trial comparing safety and durable overall response rate (DOR) at 56 days in patients with steroid resistant severe acute GvHD after allog...
    Medical condition: Steroid refractory acute GVHD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10068908 AGVHD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005276-14 Sponsor Protocol Number: RGCH004 Start Date*: 2016-06-03
    Sponsor Name:Sykehuset Østfold HF
    Full Title: Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial.
    Medical condition: Immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001557-85 Sponsor Protocol Number: 5.0 Start Date*: 2011-08-22
    Sponsor Name:Nordic Lymphoma Group
    Full Title: NLG-MCL5 (MARiT) Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 years A Nordic Lymphoma Group and British Lymphoma Group Phase-II Trial
    Medical condition: Mantle cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Temporarily Halted) DK (Prematurely Ended) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015628-27 Sponsor Protocol Number: CAUY922A2109 Start Date*: 2010-08-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib/II, multi-center, open-label study to evaluate the efficacy of AUY922 in combination with Trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer, that ha...
    Medical condition: locally advanced or metastatic HER2-positive breast cancer, that has progressed after or during at least one Trastuzumab-containing regimen
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-007081-38 Sponsor Protocol Number: M10-300 Start Date*: 2009-10-08
    Sponsor Name:Abbott GmbH & Co KG
    Full Title: An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination With mFOLFOX6 (Oxaliplatin, 5-Fluorouracil, and Folinic Acid) Versus Bevacizumab in Combination With mFOLFOX6 as Second-line Treatm...
    Medical condition: Advanced colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer PT
    9.1 10052358 Colorectal cancer metastatic LLT
    9.1 10052362 Metastatic colorectal cancer LLT
    9.1 10010030 Colorectal cancer recurrent LLT
    9.1 10010035 Colorectal cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) BE (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-019501-41 Sponsor Protocol Number: MPD-RC112 Start Date*: 2012-02-15
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia
    Medical condition: High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) SE (Ongoing) GB (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021558-21 Sponsor Protocol Number: AK106 II-02 Start Date*: 2011-02-08
    Sponsor Name:Asahi Kasei Pharma Corporation
    Full Title: A Phase IIa, Multi-Centre, Randomised, Double-Blind, Comparator Controlled, Repeated-Dose Study of 2 Dose Levels of AK106 001616 in Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-006283-30 Sponsor Protocol Number: A4061034 Start Date*: 2008-02-13
    Sponsor Name:Pfizer, S.A.
    Full Title: Estudio aleatorizado en fase 2 de Folfox o Folfiri con AG-013736 o Bevacizumab en pacientes con cáncer colorrectal metastásico después del fracaso a una pauta de primera línea con irinotecan u oxal...
    Medical condition: Segunda linea de tratamiento en pacientes con carcinoma colorectal. Second line treatment of patients with metastatic carcinoma of colon and rectum
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    9.1 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) FR (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003926-24 Sponsor Protocol Number: EGF104900 Start Date*: 2006-01-30
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A randomized, multicentre, open-label Phase III study of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with metastatic breast cancer whose disease has progresse...
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FI (Completed) HU (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Completed) GR (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 143  144  145  146  147  148  149  150  151  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 05:38:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA